Hydroxylated dimeric naphthoquinones increase the generation of reactive oxygen species, induce apoptosis of acute myeloid leukemia cells and are not substrates of the multidrug resistance proteins ABCB1 and ABCG2

Pharmaceuticals

Volumn 9, Issue 1, 2016, Pages

  Lapidus, Rena G ^a   Carter Cooper, Brandon A ^a   Sadowska, Mariola ^a   Choi, Eun Yong ^a   Wonodi, Omasiri ^a   Muvarak, Nidal ^a   Natarajan, Karthika ^a   Pidugu, Lakshmi S ^a   Jaiswal, Anil ^a   Toth, Eric A ^a   Rassool, Feyruz V ^a   Etemadi, Arash ^b   Sausville, Edward A ^a   Baer, Maria R ^a   Emadi, Ashkan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia (AML); Dimeric naphthoquinone; Oxidative stress; Reactive oxygen species (ROS)

Indexed keywords

3 BROMO 3' HYDROXY 2,2' BINAPHTHALENYL 1,4,1',4' TETRAONE; 3' CHLORO 3 HYDROXY 7 METHOXY 2,2' BINAPHTHALENYL 1,4,1',4' TETRAONE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTOTOXIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYDROXYLATION; IC50; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN EXPRESSION; UPREGULATION;

EID: 84955488809     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph9010004     Document Type: Article

References (32)

1. Buchner, T.; Schlenk, R.F.; Schaich, M.; Dohner, K.; Krahl, R.; Krauter, J.; Heil, G.; Krug, U.; Sauerland, M.C.; Heinecke, A.; et al. Acute myeloid leukemia (AML): Different treatment strategies versus a common standard arm-Combined prospective analysis by the german aml intergroup. J. Clin. Oncol. 2012, 30, 3604-3610.
2. Emadi, A.; Karp, J.E. The state of the union on treatment of acute myeloid leukemia. Leuk. Lymphoma 2014, 55, 2423-2425.
3. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5-29.
4. Holohan, C.; van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
5. Sallmyr, A.; Fan, J.; Datta, K.; Kim, K.T.; Grosu, D.; Shapiro, P.; Small, D.; Rassool, F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML. Blood 2008, 111, 3173-3182.
6. Fan, J.; Li, L.; Small, D.; Rassool, F. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative nhej pathways: Implications for genomic instability and therapy. Blood 2010, 116, 5298-5305.
7. Emadi, A.; Sadowska, M.; Carter-Cooper, B.; Bhatnagar, V.; van der Merwe, I.; Levis, M.J.; Sausville, E.A.; Lapidus, R.G. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leuk. Res. 2015, 39, 719-729.
8. Pei, S.; Minhajuddin, M.; Callahan, K.P.; Balys, M.; Ashton, J.M.; Neering, S.J.; Lagadinou, E.D.; Corbett, C.; Ye, H.; Liesveld, J.L.; et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J. Biol. Chem. 2013, 288, 33542-33558.
9. Sriskanthadevan, S.; Jeyaraju, D.V.; Chung, T.E.; Prabha, S.; Xu, W.; Skrtic, M.; Jhas, B.; Hurren, R.; Gronda, M.; Wang, X.; et al. Aml cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood 2015, 125, 2120-2130.
10. Powis, G. Free radical formation by antitumor quinones. Free Radic. Biol. Med. 1989, 6, 63-101.
11. Driscoll, J.S. Quinone structure-antitumor activity relationships. Cancer Chemother. Rep. Part 2 1974, 4, 3-4.
12. Keinan, S.; Paquette, W.D.; Skoko, J.J.; Beratan, D.N.; Yang, W.; Shinde, S.; Johnston, P.A.; Lazo, J.S.; Wipf, P. Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B. Org. Biomol. Chem. 2008, 6, 3256-3263.
13. Wellington, K.W. Understanding cancer and the anticancer activities of naphthoquinones-A review. R. Soc. Chem. (RSC) Adv. 2015, 5, 20309-20338.
14. Decosterd, L.A.; Parsons, I.C.; Gustafson, K.R.; Cardellinaii, J.H.; McMahon, J.B.; Cragg, G.M.; Murata, Y.; Pannell, L.K.; Steiner, J.R.; Clardy, J.; et al. Structure, absolute stereochemistry, and synthesis of conocurvone, a potent, novel HIV-inhibitory naphthoquinone trimer from a Conospermum sp. J. Am. Chem. Soc. 1993, 115, 6673-6679.
15. Dai, J.R.; Decosterd, L.A.; Gustafson, K.R.; Cardellina, J.H., 2nd; Gray, G.N.; Boyd, M.R. Novel naphthoquinones from Conospermum incurvum. J. Nat. Prod. 1994, 57, 1511-1516.
16. Emadi, A.; Harwood, J.S.; Kohanim, S.; Stagliano, K.W. Regiocontrolled synthesis of the trimeric quinine framework of conocurvone. Org. Lett. 2002, 4, 521-524.
17. Stagliano, K.W.; Lu, Z.; Emadi, A.; Harwood, J.S.; Harwood, C.A. Effect of methoxyl group position on the regioselectivity of ammonia substitution reactions involving 3,31-dichloro-2,21-binaphthoquinones. J. Org. Chem. 2004, 69, 5128-5131.
18. Stagliano, K.W.; Emadi, A.; Lu, Z.; Malinakova, H.C.; Twenter, B.; Yu, M.; Holland, L.E.; Rom, A.M.; Harwood, J.S.; Amin, R.; et al. Regiocontrolled synthesis and HIV inhibitory activity of unsymmetrical binaphthoquinone and trimeric naphthoquinone derivatives of conocurvone. Bioorg. Med. Chem. 2006, 14, 5651-5665.
19. Ross, A.E.; Emadi, A.; Marchionni, L.; Hurley, P.J.; Simons, B.W.; Schaeffer, E.M.; Vuica-Ross, M. Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity. BJU Int. 2011, 108, 447-454.
20. Emadi, A.; le, A.; Harwood, C.J.; Stagliano, K.W.; Kamangar, F.; Ross, A.E.; Cooper, C.R.; Dang, C.V.; Karp, J.E.; Vuica-Ross, M. Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells. Bioorg. Med. Chem. 2011, 19, 7057-7062.
21. Emadi, A.; Ross, A.E.; Cowan, K.M.; Fortenberry, Y.M.; Vuica-Ross, M. A chemical genetic screen for modulators of asymmetrical 2,21-dimeric naphthoquinones cytotoxicity in yeast. PLoS ONE 2010, 5, e10846.
22. Bey, E.A.; Reinicke, K.E.; Srougi, M.C.; Varnes, M.; Anderson, V.E.; Pink, J.J.; Li, L.S.; Patel, M.; Cao, L.; Moore, Z.; et al. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol. Cancer Ther. 2013, 12, 2110-2120.
23. Niture, S.K.; Khatri, R.; Jaiswal, A.K. Regulation of Nrf2-An update. Free Radic. Biol. Med. 2014, 66, 36-44.
24. Fletcher, J.I.; Haber, M.; Henderson, M.J.; Norris, M.D. ABC transporters in cancer: More than just drug efflux pumps. Nat. Rev. Cancer 2010, 10, 147-156.
25. Elangovan, S.; Hsieh, T.C. Control of cellular redox status and upregulation of quinone reductase NQO1 via Nrf2 activation by α-lipoic acid in human leukemia HL-60 cells. Int. J. Oncol. 2008, 33, 833-838.
26. Irwin, M.E.; Rivera-Del Valle, N.; Chandra, J. Redox control of leukemia: From molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2013, 18, 1349-1383.
27. Duthie, S.J.; Grant, M.H. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. Br. J. Cancer 1989, 60, 566-571.
28. Anusevicius, Z.; Nivinskas, H.; Sarlauskas, J.; Sari, M.A.; Boucher, J.L.; Cenas, N. Single-electron reduction of quinone and nitroaromatic xenobiotics by recombinant rat neuronal nitric oxide synthase. Acta Biochim. Pol. 2013, 60, 217-222.
29. Meyer, M.; Rubsamen, D.; Slany, R.; Illmer, T.; Stabla, K.; Roth, P.; Stiewe, T.; Eilers, M.; Neubauer, A. Oncogenic ras enables DNA damage-and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS ONE 2009, 4, e7768.
30. Sen, R.; Natarajan, K.; Bhullar, J.; Shukla, S.; Fang, H.B.; Cai, L.; Chen, Z.S.; Ambudkar, S.V.; Baer, M.R. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol. Cancer Ther. 2012, 11, 2033-2044.
31. Young, I.T. Proof without prejudice: Use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J. Histochem. Cytochem. 1977, 25, 935-941.
32. Minderman, H.; Suvannasankha, A.; O’Loughlin, K.L.; Scheffer, G.L.; Scheper, R.J.; Robey, R.W.; Baer, M.R. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 2002, 48, 59-65.